NOV 02, 2015 12:58 PM PST

Gene Splicing Induces Resistance of B Cell Leukemia to Immunotherapy

WRITTEN BY: Kara Marker
B-cell leukemia occurs in 80-85 percent of children with acute lymphoblastic leukemia (ALL), a fast-growing cancer that can be treated with CD19 chimeric antigen receptor (CAR) T-cell immunotherapy, also known as CTL019. The treatment was developed by Carl June, MD, and his team from the University of Pennsylvania beginning in 2010. It works by removing T-cells from a patient's blood and genetically modifying them to target CD19 protein present on cancerous B cells (Children's Hospital of Philadelphia).
Pre-cursor B-cell Acute Lymphoblastic Leukemia
Although the American Association for Cancer Research (AACR) reports largely positive responses from B-cell leukemia patients receiving this therapy, the treatment fails in 10-20 percent of the patients, with only some capable of being retreated successfully.

Recent research published in Cancer Discovery revealed why cancer returns resistant to CTL019 in some patients and why the treatment fails initially in others. Scientists from the Children's Hospital of Philadelphia analyzed tumor samples from pediatric patients with aggressive leukemias and found splicing alterations in the gene coding for CD19. These mutations modified the protein to the point where it is no longer recognizable by T-cells during immunotherapy. 

Gene splicing can occur in different ways, and two can cause cancer cell resistance to treatment. When exons 5 and 6 are deleted, the protein terminates prematurely and is no longer capable of attaching to the cancer cell surface to be recognized by T-cells. When exon 2 is deleted, CD19 protein is seen on the cell surface, but the modified protein is no longer targetable by treatment. 

This discovery will prompt scientists to individualize treatment and direct targets toward the mutated proteins. Plus, Andrei Thomas-Tikhonenko, PhD, and senior scientist from his lab, says the "CD19 genetic code was not irretrievably lost," hinting that there might be a way to resurrect the original protein to be targeted by immunotherapy. Thomas-Tikhonenko and team are also considering targeting other proteins present in cancer cells that are not commonly spliced as a mechanism of resistance, to avoid the troubling phenomenon all together. Ultimately, this discovery will lead to better treatment of B-cell leukemia based on individual cases of the cancer. 

Watch the following video to learn more about CTL019 and how it is used to treat other cancers like B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
 

Source: American Association for Cancer Research 

 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 13, 2019
Immunology
NOV 13, 2019
A Novel Therapeutic Target for a Severe Bacterial Infection
Pseudomonas aeruginosa (Pa) is an opportunistic human pathogen that can cause severe illness and even death in people that are hospitalized or have weakene...
NOV 13, 2019
Immunology
NOV 13, 2019
The Morel of the Story
It’s morel mushroom season in the United States and it promises to be a good one! Plenty of rain and warmth favor the growth of this delicatessen, bu...
NOV 13, 2019
Space & Astronomy
NOV 13, 2019
Spaceflight Activates Dormant Herpes Viruses in Astronauts
Modern science is teaching us that long-term exposure to microgravity, such as living on the International Space Station from ten days to several months at...
NOV 13, 2019
Health & Medicine
NOV 13, 2019
Study Links High Birth Weight to Risk of Allergies
Researchers from the University of Adelaide, Australia have linked the risk of developing childhood food allergies and eczema to heavier birth weight. The...
NOV 13, 2019
Cell & Molecular Biology
NOV 13, 2019
New RNA Observation Shows Previously Unkown Attachment to Sugar
Scientists in the Bertozzi at Staford University have published surprising observations of glycan sugars attached directly to RNA during glycosylation.&nbs...
NOV 13, 2019
Genetics & Genomics
NOV 13, 2019
Can CRISPR Replace Antibiotics?
Antibiotic-resistant infections claim around 700,000 lives per year, with estimates saying that this number could swell to 10 million by 2050 (Jacobs: 2019...
Loading Comments...